Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Ophthalmic Research, with ISSN 0030-3747 and E-ISSN 1423-0259, is a distinguished peer-reviewed journal published by Karger in Switzerland. Established in 1970, this journal serves as a vital resource for exploration and dissemination of knowledge within the fields of Ophthalmology, Cellular and Molecular Neuroscience, and Sensory Systems, maintaining its relevance through its convergence into modern research methodologies leading up to 2024. With impressive rankings in 2023, it holds a Q2 quartile in both Ophthalmology and Medicine (miscellaneous), reflecting its significant contribution to the academic community, alongside Scopus ranks that position it favorably in the competitive landscape of medical and neuroscientific literature. Although not open access, the journal ensures that high-quality research remains accessible to its readership, which includes researchers, professionals, and students eager to stay at the forefront of ophthalmic advancements. By fostering interdisciplinary collaboration and facilitating high-level discourse, Ophthalmic Research is pivotal for those committed to advancing the future of eye care and vision sciences.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

JOURNAL FRANCAIS D OPHTALMOLOGIE, published by MASSON EDITEUR, is a prominent peer-reviewed journal that serves as a vital resource in the field of ophthalmology. Launched in 1978, this esteemed publication continues to make significant contributions to the advancement of ocular health and vision science, with its scope encompassing clinical practices, innovative research, and the latest technological advancements in ophthalmic care. Based in France, the journal is recognized in the 2023 category quartiles with a Q3 ranking in ophthalmology, reflecting its dedication to quality scholarship within a competitive landscape, as evidenced by its positioning in the 30th percentile of the Scopus rankings. While it operates without Open Access, the journal remains crucial for professionals, researchers, and students alike, providing a platform for sharing knowledge and fostering collaborations in the global ophthalmological community.

The Journal of Ophthalmic & Vision Research, published by KNOWLEDGE E, stands as a crucial platform for disseminating high-quality research in the field of ophthalmology. With an ISSN of 2008-2010 and an E-ISSN of 2008-322X, this journal fosters open access to valuable insights since 2010, enhancing visibility and reach for researchers globally. Based in Dubai, UAE, it has established a reputation for excellence, reflected in its Q2 ranking in Ophthalmology for 2023 and its position among the top 65th percentile in Scopus. Covering a broad spectrum of topics within ophthalmic science, the journal serves as a vital resource for professionals, researchers, and students by presenting original research, reviews, and case studies that drive innovation and collaboration within the community. As the journal continues to contribute to advancements in eye care and vision sciences, it invites scholars to explore, engage, and publish within its pages, thus enriching the global discourse on ophthalmic health.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.

The Journal of the Korean Ophthalmological Society, with ISSN 0378-6471 and E-ISSN 2092-9374, is a pivotal resource in the field of ophthalmology, published by the esteemed Korean Ophthalmological Society. Based in South Korea, this journal is committed to advancing knowledge in ophthalmology through the dissemination of research that spans both clinical and experimental studies. Despite its current Q4 ranking in the 2023 Ophthalmology category, it serves as a crucial platform for emerging scholars, practitioners, and students seeking to contribute to and learn from the latest developments in eye care. While the journal does not currently offer open access, it is dedicated to fostering scientific dialogue and innovation within the community. With convergence years from 2018 to 2024, the journal's focus on contemporary issues in ophthalmology positions it as a relevant and timely source of information, critical for those engaged in this dynamic field. For further inquiries, the journal can be contacted at their address in Seoul, South Korea: SKY 1004 BLDG 701, 50-1 Jungnim-ro, Jung-gu, 04508.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.